image
Mesa Laboratories, Inc. MLAB
Technology - Hardware, Equipment & Parts - NASDAQ - US
Watchlist
$ 109.04
0.963 %
$ 592 M
Market Cap
-2.35
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one MLAB stock under the worst case scenario is HIDDEN Compared to the current market price of 109 USD, Mesa Laboratories, Inc. is HIDDEN

MLAB Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one MLAB stock under the base case scenario is HIDDEN Compared to the current market price of 109 USD, Mesa Laboratories, Inc. is HIDDEN

MLAB Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one MLAB stock under the best case scenario is HIDDEN Compared to the current market price of 109 USD, Mesa Laboratories, Inc. is HIDDEN

MLAB Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart MLAB

image
1M -15%
6M -22%
1Y 9%
3Y -111.0%
5Y -101%
All
$160.0$160.0$150.0$150.0$140.0$140.0$130.0$130.0$120.0$120.0$110.0$110.0$100.0$100.0$90.0$90.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
216 M REVENUE
-1.32%
Growth Rates
1Year -1.32%
3Years 17.30%
5Years 15.95%
7Years 12.69%
10Years 15.15%
-272 M OPERATING INCOME
-791.93%
Growth Rates
1Year -791.93%
3Years -271.61%
5Years -95.85%
7Years -50.73%
10Years -37.46%
-254 M NET INCOME
-27338.28%
Growth Rates
1Year -27338.28%
3Years -328.46%
5Years -103.58%
7Years -57.21%
10Years -40.16%
44.1 M OPERATING CASH FLOW
57.71%
Growth Rates
1Year 57.71%
3Years 5.98%
5Years 7.63%
7Years 28.21%
10Years 13.56%
-81.3 M INVESTING CASH FLOW
-756.39%
Growth Rates
1Year -756.39%
3Years -244.31%
5Years -83.76%
7Years -23.64%
10Years -13.39%
32.8 M FINANCING CASH FLOW
198.52%
Growth Rates
1Year 198.52%
3Years -39.22%
5Years 28.58%
7Years 17.36%
10Years 10.29%
62.8 M REVENUE
8.66%
Growth Rates
1Year -1.32%
3Years 17.30%
5Years 15.95%
7Years 12.69%
10Years 15.15%
5.78 M OPERATING INCOME
64.74%
Growth Rates
1Year -791.93%
3Years -271.61%
5Years -95.85%
7Years -50.73%
10Years -37.46%
-1.68 M NET INCOME
-48.89%
Growth Rates
1Year -27338.28%
3Years -328.46%
5Years -103.58%
7Years -57.21%
10Years -40.16%
18.4 M OPERATING CASH FLOW
249.82%
Growth Rates
1Year 57.71%
3Years 5.98%
5Years 7.63%
7Years 28.21%
10Years 13.56%
-813 K INVESTING CASH FLOW
54.53%
Growth Rates
1Year -756.39%
3Years -244.31%
5Years -83.76%
7Years -23.64%
10Years -13.39%
-10.6 M FINANCING CASH FLOW
-23.08%
Growth Rates
1Year 198.52%
3Years -39.22%
5Years 28.58%
7Years 17.36%
10Years 10.29%
Balance Sheet Mesa Laboratories, Inc.
image
Current Assets 109 M
Cash & Short-Term Investments 28.2 M
Receivables 39.1 M
Other Current Assets 42.1 M
Non-Current Assets 337 M
Long-Term Investments 0
PP&E 41.4 M
Other Non-Current Assets 296 M
6.31 %8.74 %9.42 %9.27 %66.25 %Total Assets$446.8m
Current Liabilities 44.3 M
Accounts Payable 6.04 M
Short-Term Debt 2.99 M
Other Current Liabilities 35.3 M
Non-Current Liabilities 257 M
Long-Term Debt 228 M
Other Non-Current Liabilities 28.8 M
11.71 %75.75 %9.55 %Total Liabilities$301.4m
EFFICIENCY
Earnings Waterfall Mesa Laboratories, Inc.
image
Revenue 216 M
Cost Of Revenue 82.9 M
Gross Profit 133 M
Operating Expenses 407 M
Operating Income -272 M
Other Expenses -17.8 M
Net Income -254 M
250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)216m(83m)133m(407m)(272m)18m(254m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
61.64% GROSS MARGIN
61.64%
Averages
1Year 61.64%
3Years 60.61%
5Years 60.40%
7Years 59.69%
10Years 59.62%
-125.85% OPERATING MARGIN
-125.85%
Averages
1Year -125.85%
3Years -50.27%
5Years -31.79%
7Years -21.03%
10Years -8.83%
-117.60% NET MARGIN
-117.60%
Averages
1Year -117.60%
3Years -38.72%
5Years -22.51%
7Years -15.49%
10Years -6.98%
-174.87% ROE
-174.87%
Averages
1Year -174.87%
3Years -58.05%
5Years -34.55%
7Years -24.14%
10Years -13.13%
-56.90% ROA
-56.90%
Averages
1Year -56.90%
3Years -18.83%
5Years -11.13%
7Years -7.52%
10Years -3.10%
-61.89% ROIC
-61.89%
Averages
1Year -61.89%
3Years -17.28%
5Years -10.73%
7Years -8.83%
10Years -3.59%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Mesa Laboratories, Inc.
image
45m45m40m40m35m35m30m30m25m25m20m20m15m15m10m10m5m5m00(5m)(5m)201620162017201720182018201920192020202020212021202220222023202320242024
Net Income -254 M
Depreciation & Amortization 31.6 M
Capital Expenditures -2.57 M
Stock-Based Compensation 11.9 M
Change in Working Capital 5.97 M
Others 276 M
Free Cash Flow 41.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Mesa Laboratories, Inc.
image
Wall Street analysts predict an average 1-year price target for MLAB of $120 , with forecasts ranging from a low of $120 to a high of $120 .
MLAB Lowest Price Target Wall Street Target
120 USD 10.05%
MLAB Average Price Target Wall Street Target
120 USD 10.05%
MLAB Highest Price Target Wall Street Target
120 USD 10.05%
Price
Max Price Target
Min Price Target
Average Price Target
16016015015014014013013012012011011010010090908080May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.12% DIVIDEND YIELD
0.16 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.700.700.600.600.500.500.400.400.300.300.200.200.100.100.000.000.160.160.160.160.160.160.160.160.160.160.160.160.160.160.160.160.160.160.160.160.160.160.160.160.160.160.160.160.160.160.160.160.640.160.640.160.640.160.640.160.640.160.640.160.640.160.640.160.640.160.640.162015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Mesa Laboratories, Inc.
image
Sold
0-3 MONTHS
2.6 M USD 1
3-6 MONTHS
572 K USD 1
6-9 MONTHS
187 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
What Makes Mesa Labs (MLAB) a New Strong Buy Stock Mesa Labs (MLAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com - 3 weeks ago
Why Mesa Labs (MLAB) Might be Well Poised for a Surge Mesa Labs (MLAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. zacks.com - 2 months ago
Mesa Labs (MLAB) Q3 Earnings and Revenues Beat Estimates Mesa Labs (MLAB) came out with quarterly earnings of $2.67 per share, beating the Zacks Consensus Estimate of $2.45 per share. This compares to earnings of $2.02 per share a year ago. zacks.com - 2 months ago
Mesa Labs Announces Third Quarter Results LAKEWOOD, Colo., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its third fiscal quarter (“3Q25”) ended December 31, 2024 (amounts in thousands). globenewswire.com - 2 months ago
Mesa Laboratories, Inc. to Announce Third Quarter Results on February 4, 2025 LAKEWOOD, Colo., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2025 at approximately 8:00 A.M. Eastern time on Tuesday, February 4, 2025. globenewswire.com - 3 months ago
MESA LABS DECLARES QUARTERLY DIVIDEND LAKEWOOD, Colo., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 17, 2025, to shareholders of record at the close of business on February 28, 2025. globenewswire.com - 3 months ago
Mesa Labs (MLAB) Lags Q2 Earnings and Revenue Estimates Mesa Labs (MLAB) came out with quarterly earnings of $2.45 per share, missing the Zacks Consensus Estimate of $2.48 per share. This compares to earnings of $1.91 per share a year ago. zacks.com - 5 months ago
Mesa Labs Announces Second Quarter Results LAKEWOOD, Colo., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its second fiscal quarter (“2Q25”) ended September 30, 2024 (amounts in thousands). globenewswire.com - 5 months ago
MESA LABS DECLARES QUARTERLY DIVIDEND LAKEWOOD, Colo., Oct. 02, 2024 (GLOBE NEWSWIRE) --  Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. globenewswire.com - 6 months ago
Surging Earnings Estimates Signal Upside for Mesa Labs (MLAB) Stock Mesa Labs (MLAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. zacks.com - 7 months ago
Mesa Labs (MLAB) Moves to Strong Buy: Rationale Behind the Upgrade Mesa Labs (MLAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com - 7 months ago
New Strong Buy Stocks for August 26th QFIN, GHM, CRNC, SUPV and MLAB have been added to the Zacks Rank #1 (Strong Buy) List on August 26, 2024. zacks.com - 7 months ago
8. Profile Summary

Mesa Laboratories, Inc. MLAB

image
COUNTRY US
INDUSTRY Hardware, Equipment & Parts
MARKET CAP $ 592 M
Dividend Yield 0.12%
Description Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Contact 12100 West Sixth Avenue, Lakewood, CO, 80228 https://www.mesalabs.com
IPO Date Feb. 29, 1984
Employees 736
Officers Mr. John V. Sakys CPA Vice President, Chief Financial Officer & Chief Accounting Officer Mr. Gary M. Owens Chief Executive Officer, President & Director Mr. Brian David Archbold Senior Vice President of Continuous Improvement